Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables - Other: 2017-2021

Historic Receivables - Other for Aclaris Therapeutics (ACRS) over the last 3 years, with Dec 2021 value amounting to $24,000.

  • Aclaris Therapeutics' Receivables - Other fell 92.00% to $24,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $24,000, marking a year-over-year decrease of 92.00%. This contributed to the annual value of $24,000 for FY2021, which is 92.00% down from last year.
  • As of Q4 2021, Aclaris Therapeutics' Receivables - Other stood at $24,000, which was down 0.00% from $24,000 recorded in Q3 2021.
  • Over the past 5 years, Aclaris Therapeutics' Receivables - Other peaked at $300,000 during Q2 2020, and registered a low of -$570,000 during Q4 2017.
  • For the 3-year period, Aclaris Therapeutics' Receivables - Other averaged around $139,200, with its median value being $100,000 (2019).
  • In the last 5 years, Aclaris Therapeutics' Receivables - Other skyrocketed by 200.00% in 2020 and then plummeted by 92.00% in 2021.
  • Quarterly analysis of 4 years shows Aclaris Therapeutics' Receivables - Other stood at -$570,000 in 2017, then reached $100,000 in 2019, then skyrocketed by 200.00% to $300,000 in 2020, then slumped by 92.00% to $24,000 in 2021.
  • Its last three reported values are $24,000 in Q4 2021, $24,000 for Q3 2021, and $24,000 during Q2 2021.